Additional file 1 of Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients

Additional file 1: Figure S1. Prognostic values of LANCL2 and EGFR amplification for OS and PFS in GBM patients of TCGA database. Figure S2. mRNA overexpression of LANCL2 and EGFR was not associated with prognosis of historical or IDH1/2-wild-type GBM patients. Figure S3. The prognostic values of amplification of LANCL2 or EGFR, and their co-amplification in IDH1/2-wild-type GBM patients from Shenzhen Second People’s Hospital and Sun Yat-sen University Cancer Center. Table S1. Multivariate analysis by the Cox proportional hazard regression model in a forward manner in older GBM patients (age ≥ 60 yrs) of TCGA database. Table S2. Univariate analysis for OS and PFS in IDH1/2-wild-type GBM patients of TCGA database. Table S3. Multivariate analysis by the Cox proportional hazard regression model for OS in IDH1/2-wild-type GBM patients of TCGA database. Table S4. Multivariate analysis by the Cox proportional hazard regression model in a forward manner in older GBM patients (age ≥ 60 yrs) from tumor banks. Table S5. Amplification and co-amplification of LANCL2 and EGFR in GBM samples of tumor banks. Table S6. Protein overexpression of LanCL2 and EGFR in GBM samples of tumor banks.